Hims & Hers Health (HIMS) Stock Price, News & Analysis

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hims & Hers Health in the last twelve months. There are currently 5 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HIMS shares.
View HIMS analyst ratings or view top-rated stocks.

13 Wall Street research analysts have issued 12 month target prices for Hims & Hers Health's shares. Their HIMS share price targets range from $10.00 to $20.00. On average, they predict the company's share price to reach $14.85 in the next year. This suggests a possible upside of 19.9% from the stock's current price.
View analysts price targets for HIMS or view top-rated stocks among Wall Street analysts.

Hims & Hers Health's stock was trading at $8.90 on January 1st, 2024. Since then, HIMS stock has increased by 39.1% and is now trading at $12.38.
View the best growth stocks for 2024 here.

Hims & Hers Health saw a decline in short interest in February. As of February 29th, there was short interest totaling 12,650,000 shares, a decline of 6.1% from the February 14th total of 13,470,000 shares. Based on an average trading volume of 4,040,000 shares, the short-interest ratio is currently 3.1 days. Currently, 9.1% of the company's shares are sold short.
View Hims & Hers Health's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our HIMS earnings forecast.

Hims & Hers Health will be holding an earnings conference call on Monday, May 6th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

Hims & Hers Health, Inc. (NYSE:HIMS) announced its quarterly earnings results on Monday, February, 26th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.03. The company earned $246.60 million during the quarter, compared to the consensus estimate of $245.84 million. Hims & Hers Health had a negative trailing twelve-month return on equity of 7.21% and a negative net margin of 2.70%. The company's revenue was up 47.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.05) EPS.

ETFs with the largest weight of Hims & Hers Health (NYSE:HIMS) stock in their portfolio include Amplify Online Retail ETF (IBUY), SPDR S&P Health Care Services ETF (XHS), Global X Telemedicine & Digital Health ETF (EDOC), iShares Virtual Work and Life Multisector ETF (IWFH), Fidelity Digital Health ETF (FDHT), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and Global X Millennial Consumer ETF (MILN).

Hims & Hers Health updated its first quarter 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $267.0 million-$272.0 million, compared to the consensus revenue estimate of $251.3 million.

Hims & Hers Health's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.01%), Counterpoint Mutual Funds LLC (0.01%) and Fragasso Group Inc. (0.01%). Insiders that own company stock include Alex Bard, Andrew Dudum, David B Wells, David B Wells, Irene Becklund, Jack Abraham, Jules A Maltz, Lynne Chou O'keefe, Melissa Baird, Oluyemi Okupe, Patrick Harrison Carroll, Soleil Boughton and Spencer Lee.
View institutional ownership trends.

Shares of HIMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.